Geode Capital Management
AARD

Geode Capital Management’s Aardvark Therapeutics AARD Stock Holding History

Geode Capital Management’s Portfolio AARD Stock Details AARD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.17M Buy
309,449
+11,584
+4% +$120K ﹤0.01% 3311
2025
Q4 		$3.91M Buy
297,865
+103,830
+54% +$1.3M ﹤0.01% 2897
2025
Q3 		$2.58M Buy
194,035
+57,108
+42% +$644K ﹤0.01% 3098
2025
Q2 		$1.85M Buy
136,927
+77,327
+130% +$797K ﹤0.01% 3170
2025
Q1 		$448K Buy
+59,600
New +$669K ﹤0.01% 3585

Other funds holding AARD

DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TAM
TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Geode Capital Management's AARD Position: Q1 2026 in Review

Geode Capital Management increased its Aardvark Therapeutics (AARD) stake by 3.9% in Q1 2026, buying an estimated $120K and bringing the position to 309,449 shares worth $1.17M. The position accounts for ﹤0.01% of the portfolio, ranked #3311.

Geode Capital Management first reported a position in AARD in Q1 2025 and has held it in 5 quarters since. The position peaked at $3.91M in Q4 2025. 79 funds tracked by Wall St. Rank hold AARD as of Q1 2026.

  • Geode Capital Management held 309,449 shares of Aardvark Therapeutics worth $1.17M as of Q1 2026.
  • Geode Capital Management bought 11,584 Aardvark Therapeutics shares in Q1 2026, an estimated $120K.
  • Aardvark Therapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q1 2026, its #3311 holding.
  • Geode Capital Management first reported a position in Aardvark Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • Geode Capital Management's Aardvark Therapeutics position peaked at $3.91M in Q4 2025.
  • 79 funds tracked by Wall St. Rank held Aardvark Therapeutics as of Q1 2026.

Based on Geode Capital Management's 13F filing for Q1 2026, filed 15 May 2026.